Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 7/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.37 |
| ▸ | NPC1 | O15118 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKLR | P30613 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19157860 | 0.87 | ALDH1A1 (0.40) | GRIN2BGRIN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19225348 | 0.83 | ALDH1A1 (0.36) | GRIN2BGRIN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19157477 | 0.83 | MEP1B (0.39) | GRIN2BGRIN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19220564 | 0.80 | GLA (0.33) | NPC1RAB9AALDH1A1P2RX7MEN1 | |
| SCHEMBL16016319 | 0.79 | NPC1 (0.46) | GRIN2BGRIN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16016414 | 0.76 | NPC1 (0.38) | NPC1RAB9ASMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL19225380 | 0.76 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL19157827 | 0.76 | RAB9A (0.35) | GRIN2BGRIN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL19157652 | 0.75 | NPC1 (0.38) | NPC1RAB9ASMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL19157727 | 0.73 | MPO (0.37) | GRIN2BGRIN1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3196201-B1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2021-04-28 | — | — | EP | disclosed |
| EP-3757105-A2 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | Shionogi & Co., Ltd (JP) | 2020-12-30 | — | — | EP | disclosed |
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| EP-3196201-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE-INHIBITING ACTIVITY | Shionogi & Co., Ltd. (JP) | 2017-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226128-A1 | POLYCYCLIC PYRIDONE DERIVATIVE HAVING INTEGRASE INHIBITORY ACTIVITY | TYMP, CDK6, IMPA1 | GRIN2B 3998/4885GRIN1 3337/4885NPC1 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.